Porter Home Health Location: 2400 Cumberland Dr Ste E, Valparaiso, Indiana 46383 Ratings: Phone: (219) 531-8189 Health Services: Nursing Care, Physical Therapy, Occupational Therapy, Speech Pathology, Medical Social Services, Home Health Aide |
Anchor Home Health Care Location: 1351 Silhavy Rd Ste 200, Valparaiso, Indiana 46383 Ratings: Phone: (219) 531-9400 Health Services: Nursing Care, Physical Therapy, Occupational Therapy, Speech Pathology, Medical Social Services, Home Health Aide |
First Choice Home Health Services Inc Location: 6 N Morgan Blvd Ste 101, Valparaiso, Indiana 46383 Ratings:NA Phone: (219) 464-4443 Health Services: Nursing Care, Physical Therapy, Home Health Aide |
Paragon Home Healthcare Location: 402 Wall St Ste 61, Valparaiso, Indiana 46383 Ratings: Phone: (219) 286-3212 Health Services: Nursing Care, Physical Therapy, Occupational Therapy, Speech Pathology, Medical Social Services, Home Health Aide |
Aveanna Healthcare Location: 2600 Roosevelt Rd, Suite 200-1, Valparaiso, Indiana 46383 Ratings:NA Phone: (219) 548-0099 Health Services: Nursing Care, Home Health Aide |
News Archive
This study demonstrates that the distinction between threshold and subthreshold anorexia nervosa does not seem to be of clinical relevance in terms of response to cognitive-behavioral therapy (CBT). Shape concern rather than demographic or general psychopathological features represents the best predictor of outcome for CBT.
An international consortium led by researchers in Sweden and Switzerland has conducted a genome-wide study that the team is calling a "medical breakthrough" in malaria research.
Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today reported the successful results of its Phase 2b trial for once-daily, quadruple-action RoclatanTM, a combination of Aerie's triple-action RhopressaTM with latanoprost, a prostaglandin analogue (PGA).
Home Diagnostics, Inc., a leading manufacturer and marketer of diabetes testing supplies, announced today that it signed a definitive merger agreement with Nipro Corporation (Tokyo Stock Exchange and Osaka Stock Exchange Ticker Code 8086), a global manufacturer and distributor of medical devices, pharmaceutical products and medical and glass products headquartered in Osaka, Japan, under which Nipro will acquire all outstanding shares of Home Diagnostics' common stock, $.01 par value, for a cash purchase price of $11.50 per share (or aggregate consideration of approximately $215 million).
› Verified 5 days ago